isolate of HIV. Pharmacological inhibition of synthesis of selected PA species may therefore provide a therapeutic approach to suppression of HIV replication.
Human immunodeficiency virus (HIV) infection leads to progressive depletion of CD4+ T lymphocytes and eventual development of clinical symptoms associated with AIDS. Following primary infection with HIV, there is a prolonged incubation period of clinical latency that can last as long as 12 years (1) . During this asymptomatic phase of the disease, viral replication occurs continuously (1) and multiple components of the immune system are chronically activated (2) . Persistent activation of the immune system may lead to overproduction of a number of cytokines (2) , induction of HIV expression in latently infected cells (3) , and apoptosis of T cells (4) .
The HIV genome has been studied to elucidate regulatory mechanisms and points for potential therapeutic intervention (5) . All the genes of HIV, like those of other retroviruses, are expressed under the control of the strong promoter within the viral long terminal repeat (LTR) (5, 6) . High levels of HIV expression require binding of the HIV trans-activator protein Tat (5, 6) to the trans-activation response (TAR) element found within the HIV LTR. Other unique DNA and RNA elements in the HIV LTR have made this region an important target for regulation by cellular and viral proteins. The LTR promoter contains cis-acting repressive sequences that inhibit
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
HIV transcription initiation in resting T cells (7) . However, mitogenic stimulation by cytokines, such as tumor necrosis factor a (TNF-a), interleukin 1, 3 (IL-1p3), and IL-6, induces HIV synthesis in infected cells primarily through activation and binding of NF-KB transcription factors to sites within the HIV LTR (2) .
Phosphatidic acids (PAs) are a molecularly diverse group of phospholipid second messengers coupled to cellular activation and mitogenesis (8) . Specific PAs that are generated during cellular activation with IL-1, IL-2, or lipopolysaccharide have been identified (8) (9) (10) (11) , and a series of compounds that suppress production of selected PAs have been synthesized (8 
MATERIALS AND METHODS
Lipid Analysis. Cells were incubated in medium with 0.1% calf serum overnight and then stimulated with 10% serum for various times. Lipids were extracted by the Folch method as described (10) . Phospholipids in cells were separated by HPLC using anisocratic gradients (9, 10 (47) . CT-2576 and related compounds were obtained from the library of synthetic smallmolecule PA inhibitors developed at Cell Therapeutics (Seattle). Cytotoxicity of CT-2576 was assayed with AlamarBlue dye (Alamar Biosciences, Sacramento, CA). The assays of HIV-1 p24 antigen expression in the chronically HIV-1-infected promonocytic line Ul and in acutely infected peripheral blood lymphocytes (PBLs) were described previously (19, 20) .
NF-KB binding activity in nuclear extracts (21) of cells was measured by electrophoretic mobility-shift assay (EMSA) (22) using 5'-labeled double-stranded synthetic DNA with two NF-KB motifs (6) . Northern blot analysis was performed with total RNA run in a 1% agarose/formaldehyde gel and probed with 32P-labeled cDNAs of AP and glyceraldehyde-3-phosphate dehydrogenase.
RESULTS
CT-2576 Inhibits Tat-Induced Accumulation ofPA in 293tat Cells. Cell activation signals generated by interaction of ligands with receptors are eventually converted to changes in the pattern of gene expression. One of the steps after cell activation in the signal transduction cascade involves the hydrolysis of GPI by GPI-specific phospholipase D, leading to the generation of PA second messenger (11) (12) (13) . In addition to enhancing HIV transcription and replication (5, 6) , Tat is an important activator of certain cellular genes and functions (23) (24) (25) (26) (27) . The effects of Tat on phospholipid composition are not well understood. Its effects on phospholipid composition in 293EBNA cells were therefore analyzed by HPLC (Fig. 1A) . pHIV.tat (293tat cells) or pSV2tat72 (293tat4 cells). In cells stimulated with serum for 1 hr, analysis of the PA species eluted at 5 min (Fig. 2) showed 293tat cells had higher levels of this PA than control 293EBNA or 293LTR cells (Fig. 1A) . Prior fast-atom-bombardment mass spectroscopy studies have shown that the peak at this elution position in T cells contained PA (11) . To see whether CT-2576, a compound that inhibits IL-2-induced hydrolysis of GPI to PA in T cells (11) (12) (13) , would affect the level of Tat-induced PA, serum-starved 293tat cells were treated with 2 ,uM and 8 AM CT-2576 for 1 hr prior to analysis of phospholipid contents by HPLC at various times after serum stimulation. Both concentrations of CT-2576 suppressed PA accumulation in 293tat cells (Fig. 1B) . Examples of HPLC analysis of phospholipid contents (10, 28) 293tat cells without or with 8 ,uM CT-2576 preincubation are shown in Fig. 2 . These HPLC scans are representative of triplicates from several experiments, in which variances in phosphatidylethanolamine and phosphatidylcholine peaks used for normalization were <11% at each time point. The chromatogram traces show suppression of the PA peak (5 min) and elevation of the peak area corresponding to GPI (20 min) seen in T cells (11) . These data suggest that CT-2576 inhibits the generation of PA through suppression of GPI hydrolysis in 293tat cells. However, changes in other lipids, such as those indicated by PK.B, PK.C, and PK.D in Fig. 2 , may also be contributing to the effects of CT-2576 and require further investigation.
CT-2576 Inhibits TNF-a-and Tat-Activated HIV LTR Promoter-Directed Expression in 293tat Cells. Fig. 3 shows AP reporter gene activity expressed in 293EBNA cells transiently transfected with HIV LTR-reporter gene constructs alone or in combination with tat expression vectors. Also shown is the effect of TNF-a on reporter gene expression in the transfected cells. The expression level of AP was low (1.0 ± 0.4 milliunit) for the pHIVl.AP construct alone. TNF-a increased its expression "4-fold (3.8 ± 0.4 milliunits). AP expression increased in the presence of pSV2tat72 or pHIV.tat by 70-and 15-fold, respectively. These data were consistent with a previous report that tat expression directed by the simian virus 40 early promoter was higher than that directed by the HIV LTR in cotransfection assays (29) . TNF-a and Tat in combination further enhanced the AP expression level by 2-fold when the pSV2tat72 construct was used, and by 10-fold when the pHIV.tat construct was used, reaching nearly identical levels of expression. pHIV2.AP, which has the sequence hr with or without TNF-a (20 ng/ml). Two microliters of medium from each well was used for AP assay. Bars represent the mean and SD of triplicate samples.
upstream of the NF-KB sites deleted, and pHIV3.AP, which has the NF-KB sites and the upstream sequence deleted, have a higher constitutive level of AP expression (9.3 ± 0.8 and 3.4 ± 0.5 milliunits, respectively) than pHIVl.AP, indicating the presence of negative regulatory elements in the HIV LTR (7). Both deletion constructs can be activated by Tat. In contrast to Tat activation, TNF-ca can activate cells transfected with pHIV2.AP, but not pHIV3.AP.
The effect of CT-2576 on HIV promoter activity in transfected cells is shown in Fig. 4 CT-2576 Does Not Affect the Activation of NF-cB in 293tat Cells. TNF-a signaling occurs through NF-KB activation (30) . To determine whether CT-2576 was inhibiting promoter activation through NF-KB or downstream of transcription, EMSA and Northern analysis of AP mRNA levels were performed. EMSA (Fig. SA) showed NF-KB was activated in 293tat cells upon induction with either TNF-a or IL-1f, and CT-2576 did not inhibit this activation of NF-KB. Northern blot analysis (Fig. SB) showed increased levels of AP transcripts following cytokine treatment. Although there was a >80% decrease in secreted AP activity after cytokine induction in the presence of CT-2576, AP mRNA levels were increased in the presence r. TNF-ca (20 ng/ml). Two microliters of medium from each well was used for AP assay 24 hr later. After culture medium was withdrawn for AP assay, cytotoxicity was measured for the same cell cultures by using an indicator dye, AlamarBlue (right y axis). Data represent the mean and SD of triplicate samples. of CT-2576. Taken together, these data suggest that CT-2576 blocks expression of AP via a pathway independent of transcriptional events.
CT-2576 Inhibits Both Constitutive and Cytokine-Induced HIV Expression in the Chronically Infected Cell Line Ul. The effect of CT-2576 on viral replication in the chronically HIV-1-infected human promonocyte cell line Ul (19, 31) was tested to examine the ability of HIV LTR-driven reporter gene expression to predict the effect of CT-2576 on HIV replication. TNF-a and IL-6 have been reported to upregulate the expression of HIV-1 in Ul cells (31) . CT-2576 inhibited constitutive as well as TNF-a-and IL-6-induced expression of HIV in Ul cells with an IC50 value of -1 ,uM (Fig. 6) .
A CT-2576-Related Compound Also Inhibits HIV Expression in Acutely Infected Cells. Viral isolates from infected individuals can behave quite differently from laboratoryadapted strains (20) . An acetylated derivative of CT-2576 with similar activities in the promoter-based assay, CT-3537, was tested on human PBLs freshly infected with a clinical isolate HIV-1 strain JR-CSF (20) . Analysis of p24 antigen release 7 days later showed'that CT-3537 inhibited HIV expression with an IC50 of 1 ,uM (Fig. 6 ). DISCUSSION Drugs currently approved for AIDS therapy belong to a class of compounds which inhibit viral reverse transcriptase (32) . A recent study (33) on the use of 3'-azido-3'-deoxythymidine (AZT) for the treatment of asymptomatic patients in the early stage of HIV infection showed that inhibitors of reverse transcriptase did affect markers such as CD4+ T-cell counts but showed no survival benefit to early treatment. Like other antiviral agents targeting HIV protease, they are subject to the emergence of resistant strains of HIV (14, 46 (23) (24) (25) (26) (27) 35) . Another possible mechanism for Tat-associated cellular activation is described in the present study. Compared with control cells, 293tat cells overexpress PA, which has been associated with cell activation and mitogenesis in lymphocytes (11) (12) (13) (Fig. 1A) . CT-2576, an inhibitor of the generation of PA in CT6 cells (11) , inhibits production of Tat-and TNF-a-induced protein from the HIV LTR-directed AP gene with minimal cytotoxicity (Fig. 4) .
EMSA and Northern blot analysis showed CT-2576 did not block NF-KB activation or transcription from the HIV LTR (Fig. 5) . It is possible that inhibiting the accumulation of PA by CT-2576 may lead to inhibition of translation of certain proteins. Mechanisms of signaling that involve activation of translational machinery'components have been described recently (36) (37) (38) . In addition, certain phospholipids have been found to affect in vitro translation (39, 40) . The mode of action of CT-2576 is therefore different from that of (41) , a compound that blocks HIV LTR promoter transcription through interaction with Tat. Because of its unique mechanism of action, CI-2576 may have a synergistic effect with other anti-HIV compounds. CT-2576 should also be effective in suppressing HIV expression in cell types with constitutive NF-KB activity, such as certain neurons involved in the etiology of AIDS dementia complex (42) .
To (44) . While TNF-a induces HIV expression through activation of NF-KB, IL-6 and IL-1 also stimulate HIV expression through pathways independent of NF-KB in Ul cells (31) . Ul cells also express HIV constitutively when grown to a relatively high density. CT-2576 inhibited constitutive as well as TNF-a-and IL-6-induced expression of HIV-1 p24 antigen in Ul cells (Fig. 6) (45) will be required to determine whether sufficient antiviral effects can be achieved through this approach. 
